Govt proposes tighter scrutiny of antimicrobial drugs to address resistance worries
The government is proposing amendments to the New Drugs and Clinical Trials Rules, 2019 for antimicrobial medicines. This amendment would require manufacturers to seek permission from the Central Licensing Authority before obtaining state manufact...
The proposed amendment to the New Drugs and Clinical Trials Rules, 2019, will require manufacturers to obtain permission from the Central Licensing Authority (CLA) before approaching state licensing authorities for manufacturing licences for antimicrobial products.

"The requirement will apply prospectively, with the government clarifying that existing manufacturing licences will remain valid and current licence holders will not have to seek fresh approvals," an official said.
The health and family welfare minitry has proposed the amendment through a draft notification seeking to include 'antimicrobials' in the definition of a 'new drug' under Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019.
The ministry said the proposal was intended to serve as an additional regulatory safeguard against AMR by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before new manufacturing licences are granted.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.